News | October 30, 2025
Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr
Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025
Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
The antibody was designed and developed at Abzena’s Cambridge, UK,
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Subscribe To Our Newsletter & Stay Updated
